Abu Dhabi is advancing its healthcare ecosystem from observational genomic sequencing to direct clinical intervention, preparing to launch its first in-vivo gene-editing trials before the end of 2026.
The upcoming clinical study represents a formal strategic alliance between the Department of Health Abu Dhabi, regional healthcare leader M42, and US biotechnology enterprise Mammoth Biosciences. Announced in July, the partnership encompasses clinical research execution, site qualification, medical team certification, and the eventual establishment of local advanced therapy manufacturing capabilities within the United Arab Emirates.
The initial candidate identified for the landmark clinical evaluation is persistent chylomicronemia, a severe inherited metabolic condition that elevates blood fat to dangerous levels and frequently triggers severe, recurring attacks of pancreatitis. Beyond metabolic disorders, the partnership is structuring clinical trial protocols for sickle cell disease and beta-thalassemia, two inherited blood conditions prevalent across the Middle East that subject patients to chronic pain, severe anaemia, and lifetime dependencies on blood transfusions.
“The ambition is to begin before the end of this year,” Albarah El Khani, Senior Vice President, Operations at M42 tells Arabian Business.
For global biotech investors, pharmaceutical multinationals, and clinical research organizations operating across international hubs such as Singapore, London, and Boston, Abu Dhabi’s rapid scaling of advanced therapy infrastructure presents immediate commercial and research opportunities. The initiative establishes a high-value clinical pipeline in the Middle East, supported by robust sovereign backing and structured regulatory frameworks.
Next Generation Delivery Systems Bring Advanced Gene Therapy Directly to the Patient
The treatment platform under active development aims to deliver a specialized gene-editing tool directly inside the human body. Once administered, the delivery system navigates through the bloodstream to target bone marrow stem cells, correcting the pathogenic genetic mutation in situ.
This methodology stands in sharp contrast to conventional ex-vivo gene-editing procedures, which require clinicians to extract stem cells from a patient, modify them in specialized off-site laboratories, and reinfuse them following intensive conditioning chemotherapy. The in-vivo approach developed in collaboration with Mammoth Biosciences eliminates ex-vivo manipulation, though the process remains under active refinement pending formal clinical and regulatory validation.
Mammoth Biosciences was co-founded by Jennifer Doudna, who shared the 2020 Nobel Prize in Chemistry for her seminal work on CRISPR gene editing. The company utilizes ultra-compact gene-editing systems designed to access biological tissues that historically proved inaccessible to larger, first-generation viral vector platforms.
Beyond hosting trial sites, Abu Dhabi is leveraging the program to institutionalize clinical capabilities within its domestic health network. International medical teams with established experience in executing these advanced therapies will train local personnel during the initial phase.
“One of the most important pieces of this isn’t just the science, it’s the people delivering it. A major part of the plan is training Abu Dhabi’s health system to safely administer these therapies, building genuine local expertise rather than relying on it being flown in indefinitely. In the early stages, international medical teams experienced with these treatments will come to Abu Dhabi to train local clinicians directly, so that capability is built here rather than imported each time,” El Khani says.
Formal trial sites remain under selection, while long-term safety oversight and ethical trial governance fall directly under the authority of the Department of Health Abu Dhabi.
Leveraging Massive Genomic Repositories for Targeted Precision Medicine
The technical foundation for candidate selection relies heavily on the Emirati Genome Programme, which has processed and cataloged over 900,000 whole genomes to date. The database forms a massive, population-level repository that enables clinical researchers to isolate specific inherited risks and recruit eligible participants under strict medical privacy standards.
In persistent chylomicronemia, the genomic dataset allows researchers to pinpoint individuals holding the specific genetic mutation and compare them against patients whose lipid disorders stem from non-genetic triggers like diet, metabolic comorbidities, or medication interactions.
The data infrastructure is already supporting parallel clinical studies. In June, M42’s Insights Research Organization and Solutions launched the UAE’s inaugural genomics-driven trial targeted at Alzheimer’s disease prevention, screening Emirati Genome Programme data to identify individuals carrying high-risk genetic variants prior to symptom onset.
Complementing genomic data, the Abu Dhabi Biobank offers capacity for 100,000 cord blood samples and five million biological specimens. Linked with electronic health records and lifestyle metrics, this infrastructure grants researchers an unprecedented repository tailored specifically to Arab genomes, a demographic historically underrepresented in global clinical trials.
HELM Cluster Drives 94 Billion AED Economic Expansion in Masdar City
Abu Dhabi’s healthcare initiatives are tightly integrated with its broader economic diversification agenda, supported by government grants, dedicated lab space, and specialized industry clusters designed to bridge academia and commercial output.
The Health, Endurance, Longevity and Medicine cluster, known as HELM, received official approval in April 2025. Projections indicate the cluster could contribute over 94 billion AED to Abu Dhabi’s gross domestic product, attract 42 billion AED in foreign direct investment, and create approximately 30,000 high-skilled positions by 2045.
Masdar City serves as the primary physical anchor for the cluster, developing state-of-the-art laboratory infrastructure via agreements with the Department of Health Abu Dhabi and the Abu Dhabi Investment Office. AI-driven drug discovery firms, clinical research entities, and biotech incubators have established early operational footholds at the site.
In June, partners unveiled Biosphere Labs during the BIO International Convention in San Diego, launching what is recognized as the GCC region’s first commercially scaled shared life sciences laboratory. The facility grants early-stage biotech ventures access to specialized wet labs and operational support without requiring massive capital outlay.
“The purpose of both is to remove the barriers that usually sit between a founder and a working lab, cutting the time, cost and complexity involved in setting one up independently. For most early-stage biotechs, especially ones doing wet-lab work, lab space is normally the single biggest fixed cost and the longest lead time before a company can even start operating, often a year or more to fit out a compliant facility independently. Removing that barrier is what lets a founder go from idea to bench in weeks instead. It’s also how a market with a small number of biotech founders per capita builds a critical mass of them physically in one place, which is where a lot of the informal collaboration and hiring happens,” Al Breiki says.
Financial frameworks are adapting concurrently, underscored by the federal Research and Development Tax Incentives Programme launched in March, which grants qualifying enterprises tiered tax credits up to 50 percent on eligible local research expenditures.
Resolving Supply Chain Gaps and Expanding Regional Manufacturing Capacity
Despite massive strides in genomics and clinical research, localized bio-manufacturing remains an operational bottleneck across the Middle East. Most critical research consumables and therapeutic components are currently imported through global supply chains, limiting domestic value capture.
“Manufacturing and supply chain capacity is the clearest example, and it’s an area Masdar City is actively building out. Discovery, preclinical and clinical development already have strong anchors on our site (Insilico Medicine, Attentive Science, IROS), and manufacturing and cold-chain capacity is the next layer coming online as the pipeline of licensed companies matures,” Al Breiki says.
The M42 and Mammoth Biosciences alliance includes framework agreements to localize the synthesis of lipid nanoparticles, essential transport vectors for delivering gene-editing packages into target cells. While long-term agreements envision fully integrated advanced therapy manufacturing in Abu Dhabi, explicit production timelines remain unannounced.
Looking ahead, regional stakeholders are moving to bridge growth-stage funding gaps, ensuring early-stage discoveries transition smoothly into mid-phase clinical trials. Supported by long-term residency visas, academic partnerships with Khalifa University and Mohamed bin Zayed University of Artificial Intelligence, and targeted international recruitment, Abu Dhabi is positioned to cement its status as an international powerhouse for biotechnology and precision medicine over the coming decade.
